Novo Nordisk’s (NVO) GLP-1 weight reduction medication, Ozempic and Wegovy, shall be focused within the subsequent spherical of Medicare worth negotiations in 2027, together with 13 different medicines.
Seana Smith and Brad Smith break down the small print on Morning Transient.
The final spherical of the Inflation Discount Act (IRA) negotiations gave Medicare a median 22% worth discount for the medication on this record. With $41 billion in annual Medicare spending on these medication, the implications for healthcare prices — particularly weight problems therapies — are large. Nonetheless, questions loom round regulatory choices below a brand new Trump administration, including complexity to future outcomes.
To look at extra skilled insights and evaluation on the most recent market motion, take a look at extra Morning Transient here.
This submit was written by Josh Lynch
Source link